1. Cumulated Activity Comparison of 64 Cu-/ 177 Lu-Labeled Anti-Epidermal Growth Factor Receptor Antibody in Esophageal Squamous Cell Carcinoma Model.
- Author
-
Laffon E, Thumerel M, Jougon J, and Marthan R
- Subjects
- Animals, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Computer Simulation, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms pathology, Metabolic Clearance Rate, Mice, Models, Biological, Positron-Emission Tomography methods, Radiation Dosage, Radioisotopes pharmacokinetics, Radiopharmaceuticals pharmacokinetics, Tissue Distribution, Antibodies, Monoclonal pharmacokinetics, Carcinoma, Squamous Cell metabolism, Copper Radioisotopes pharmacokinetics, ErbB Receptors metabolism, Esophageal Neoplasms metabolism, Lutetium pharmacokinetics
- Abstract
This work aimed at estimating the kinetic parameters, and hence cumulated activity (A
C ), of a diagnostic/therapeutic convergence radiopharmaceutical, namely64 Cu-/177 Lu-labeled antibody (64 Cu-/177 Lu-cetuximab), that acts as anti-epidermal growth factor receptor. Methods: In mice bearing esophageal squamous cell carcinoma tumors, to estimate uptake (K), release rate constant (kR ), and hence AC , a kinetic model analysis was applied to recently published biodistribution data of immuno-PET imaging with64 Cu-cetuximab and of small-animal SPECT/CT imaging with177 Lu-cetuximab, including blood and TE-8 tumor. Results: K, kR , and AC were estimated to be 0.0566/0.0593 g⋅h-1 ⋅g-1 , 0.0150/0.0030 h-1 , and 2.3 × 1010 /4.1 × 1012 disintegrations (per gram of TE-8 tumor), with an injected activity of 3.70/12.95 MBq, for64 Cu-/177 Lu-cetuximab, respectively. Conclusion: A model is available for comparing kinetic parameters and AC of the companion diagnostic/therapeutic64 Cu-/177 Lu-cetuximab that may be considered as a step for determining whether one can really use the former to predict dosimetry of the latter., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2017
- Full Text
- View/download PDF